Recombinant Mouse Tpp1 protein, His-tagged

• Cat.No.: Tpp1-20M
• Product Overview: Recombinant Mouse Tpp1(Gly198~Pro562) fused with His tag at N-terminal was expressed in E. coli.

Specification

• Description: This gene encodes a lysosomal serine protease that cleaves N-terminal tripeptides from protein substrates. The encoded preproprotein undergoes autocatalytic processing to generate a mature enzyme. Mice lacking the encoded protein exhibit a progressive neurodegeneration and a greatly shortened lifespan. At the cellular level, mice lacking the encoded protein exhibit accumulation of autofluorescent lipopigments. Mutations in the human ortholog of this gene cause classical late-infantile neuronal ceroid lipofuscinosis.
• Source: E. coli
• Species: Mouse
• Tag: His
• Form: PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
• Molecular Mass: 43.2kDa
• Protein length: Gly198~Pro562
• Endotoxin: <1.0EU per 1µg (determined by the LAL method)
• Purity: >95%
• Applications: Positive Control; Immunogen; SDS-PAGE; WB.
  If bio-activity of the protein is needed, please check active protein.
• Stability: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 centigrade for 48h, and no obvious degradation and precipitation were observed. The loss rate is
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8 centigrade for one month. Aliquot and store at -80 centigrade for 12 months.
• Reconstitution: Reconstitute in PBS or others.

Gene Information

• Gene Name: Tpp1 tripeptidyl peptidase I [ Mus musculus ]
• Official Symbol: Tpp1
• Synonyms: TPP1; tripeptidyl peptidase I; tripeptidyl-peptidase 1; LPIC; TPP-1; tripeptidyl peptidase-I; tripeptidyl-peptidase I; tripeptidyl aminopeptidase; ceroid-lipofuscinosis, neuronal 2; lysosomal pepstatin-insensitive protease; Cln2; TPP-I
• Gene ID: 12751
• mRNA Refseq: NM_009906
• Protein Refseq: NP_034036
• UniProt ID: O89023

Reviews

06/23/2019

These resources can enhance the efficiency and accuracy of experimental workflows and contribute to successful outcomes.

12/07/2018

The manufacturer's support is crucial for researchers using TPP1 protein in trials.

09/16/2018

Their collaboration, expertise, and customized solutions contribute to the successful execution of experiments, reliable data generation, and the advancement of scientific knowledge in the field.

Q&As

Are there any specific inhibitors developed to target PKMYT1?

Yes, several PKMYT1 inhibitors are under development and in preclinical and clinical trials for evaluating their efficacy in cancer treatment.

Are there ongoing clinical trials targeting PKMYT1?

Yes, several clinical trials are investigating the efficacy of PKMYT1 inhibitors in various cancer types.

How does PKMYT1 influence cell cycle progression?

PKMYT1 regulates the cell cycle by inhibiting the activity of cyclin-dependent kinases (CDKs), particularly CDK1, which is crucial for G2/M phase transition.

Can PKMYT1 be used as a predictive biomarker in cancer patients?

Yes, the expression levels of PKMYT1 can be indicative of the responsiveness of cancer cells to specific treatments, making it a potential predictive biomarker.

How does PKMYT1 inhibition affect normal cell function?

Selective PKMYT1 inhibitors aim to minimize effects on normal cells, but potential impacts on the cell cycle of non-cancerous cells are still under investigation.